RESEARCH TRIANGLE PARK, N.C. - BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the following conferences:

The Bank of America Securities 2022 Healthcare Conference in Las Vegas, NV on Tuesday, May 10, 2022, at 11:00 a.m. ET.

The RBC Capital Markets Global Healthcare Conference in New York on Wednesday, May 18, 2022 at 1:35 p.m. ET.

The H.C. Wainwright Global Investment Conference - pre-recorded fireside chat available beginning Tuesday, May 24, 2022 at 7:00 a.m. ET.

Links to a live audio webcast and replay of these presentations may be accessed in the Investors & Media section of BioCryst's website at http://www.biocryst.com.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO (berotralstat) is approved in the United States, the European Union, Japan, the United Kingdom and the United Arab Emirates. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB (peramivir injection) has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the company's website at www.biocryst.com.

Contact:

Investor

John Bluth

T: +1 919 859 7910

E: jbluth@biocryst.com

(C) 2022 Electronic News Publishing, source ENP Newswire